100 High Myopia Patient-reported Outcomes (PRO) and Performance Outcomes (PERFO)
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Quality of life questionnaire, Performance Outcomes (PerfO), Semi-structured interviews.
- Who it may be relevant to
- Registry conditions: High Myopia. Basic parameters: 18 years — 55 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Pathological Myopia and Quality of Life: An Exploratory Study of Patient Outcomes and Perceptions
Overview
Prospective, longitudinal, interventional, exploratory, non-randomized, single-center study including patients with pathological myopia .
Detailed description
This project will be conducted in two phases, with a qualitative study and an exploratory phase.
There is a clinical need to better understand the progression of myopic complications with diffuse choroidal atrophy (DCA Cat. 2) and choroidal patch atrophy (CPA Cat. 3) and their impact on everyday life.
The first phase is a qualitative study whose objectives are
1. to study the parameters (ceiling and floor effects) and assess the reliability of performance tasks in relation to perceived difficulties, 2. to use interviews to gather information on the difficulties reported in everyday life, the causes, and the environmental conditions leading to a reduction in activity in a population of myopic patients with retinal complications.
The second phase will consist of a quantitative exploratory pilot study aimed at comparing the performance of diffuse choroidal atrophy (DCA) and choroidal patch atrophy (CPA) patients in order to highlight any differences between the two in tasks involving mobility and obstacle avoidance, visual search, and driving
Interventions
- Other Quality of life questionnaire
The NEI-RQL-42 (National Eye Institute Refractive Quality of Life) questionnaire will be self-administered via a secure online platform to assess the impact of pathological myopia on quality of life. - Other Performance Outcomes (PerfO)
Three tests are planned to assess the impact of high myopia on critical aspects of mobility and safety, with the possibility of adjusting their scope based on pilot data. * The first test involves an assessment of driving on a simulator, designed to evaluate the performance of detecting pedestrians in peripheral vision, with and without glare. * The second test focuses on assessing mobility and obstacle avoidance under six levels of brightness. * The third test evaluates visual search ability. - Other Semi-structured interviews
Semi-structured interviews will only be offered to patients recruited in Phase 1 Qualitative and aim to further explore the information gathered from the NEI-RQL-42 questionnaire responses and the difficulties encountered during the performance tasks in the laboratory, by exploring in more detail the limitations encountered by patients with pathological myopia in their daily activities. These interviews will help identify the specific causes of the difficulties encountered, as well as the enviro
Primary outcome measures
- Simulator driving test:Evaluation of pedestrian detection performance using peripheral vision [Time frame: 2 months]
- Locomotion assessment [Time frame: 2 months]
- Visual search in VR [Time frame: 2 months]
Eligibility criteria
Inclusion criteria
Patients with pathological myopia and diffuse choroidal atrophy (DCA, Cat. 2 Meta PM)
- Age ≥ 18 years and ≤ 55 years;
- Patient consenting to be included in the study;
- Examination and follow-up in at least one of the participating centers;
- Severe pathological myopia with an axial length ≥ 26.5 mm in both eyes;
- Presence of diffuse atrophy (category 2 of the Meta-PM classification) in the better eye;
- Affiliated with or covered by a social security system.
Pathological myopic patients with patch choroidal atrophy (PCA,
Cat. 3 Meta PM):
- Age ≥ 18 years and ≤ 55 years;
- Patients who consent to be included in the study;
- Examination and follow-up at least one of the participating centers;
- High myopia with an axial length ≥ 26.5 mm in both eyes;
- Presence of patch atrophy (category 3 of the Meta-PM classification) in the better eye;
- Affiliated with or beneficiary of a social security system.
Exclusion criteria
- Identified genetic syndromic myopia, including Stickler syndromes type 1 and 2 (collagen 2A1 and 11A1), Marfan syndrome (fibrillin), Ehler-Danlos syndrome type 4 (lysyl-protocollagen hydroxylase), and Knobloch syndrome (collagen 18A).
- Patient unwilling to participate or be followed up at one of the participating centers.
- Binocular visual acuity ≥ 1 logMar (<0.1 on the decimal scale).
- Media opacities preventing quality imaging, including cataracts.
- Patients benefiting from legal protection measures.
- Pregnant or breastfeeding women.
- Individuals who may not be able to tolerate the driving simulator.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Non-randomized
- Model
- Parallel assignment
- Masking
- Open label
- Primary purpose
- Other
Study locations
Center list to be confirmed — check the primary protocol.
Identifiers
NCT: NCT07101146 · P22-06